We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 27, 2022

Patritumab Deruxtecan in Patients With HER3-Expressing MBC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
J. Clin. Oncol 2022 Jun 01;40(16 suppl)1002, IE Krop, N Masuda, T Mukohara, et al

Further Reading